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Background: The proportion of patients with cystic fibrosis (CF) who are middle-aged is
increasing e and is likely to continue to do so. We surveyed a population of long-term CF
survivors to assess their burden of illness and profile their disease characteristics.
Methods: A case series (nZ 112) of patients from one specialist centre who had reached their
40th birthday without transplantation. Hospital records and annual review data were examined.
Results: The median age of the group was 43.1 years (range 40e71.1); 57% were men. 68% were
diagnosed before 16 years of age. 30% were DF508/DF508, 76% having at least one DF508 allele.
When compared with the total adult CF population, the older patients were significantly less
likely to have a DF508 mutation or colonisation with Stenotrophomonas maltophilia and MRSA;
but more likely to have pancreatic sufficiency, colonisation with Pseudomonas aeruginosa or
allergic bronchopulmonary aspergillosis. On average they required less than one hospital
admission a year; lung function and body mass index were relatively well preserved. Many were
married and working.
Conclusions: We describe one of the largest surveys to date of CF patients aged more than 40
years. The full spectrum of disease is represented in this population and, importantly, 30% are
DF508 homozygous. Provision needs to be made for the healthcare needs of this increasing
population of older patients.
ª 2008 Elsevier Ltd. All rights reserved.opulmonary aspergillosis; BMI, body mass index; CF, cystic fibrosis; CFRD, cystic fibrosis related
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630 N.J. Simmonds et al.Introduction potential difference measurement. Data are updated eachCystic fibrosis (CF) causes premature death, usually as
a result of recurrent pulmonary infections progressing to
respiratory failure. Despite the lack of any cure, survival
rates have progressively increased since CF was first iden-
tified as a specific disease entity in 1938 - when over 70%
patients died in their first year of life.1 The current median
survival is 36.8 years2 and children born in the 2000s are
now predicted to have a median survival into their 50s.3
Importantly, in many countries there are now more adults
with CF than children.4 Consequently, increasing numbers
of CF adults reaching middle age or older are predicted for
the future.
The explanations for improved survival are complex and
likely to be influenced by clinical characteristics (genetic
and non-genetic), healthcare provision, the environment
and socioeconomic factors.5 The term ‘CF’ covers a spec-
trum of disease, now sub-classified into classic (or typical)
and non-classic (or atypical) disease.6 The diagnosis of
classic CF is usually straightforward, whereas non-classic CF
can be a diagnostic dilemma, characterised by an equivocal
(or normal) sweat chloride and, in the absence of confir-
matory genotyping, requiring further quantification of CF
transmembrane conductance regulatory (CFTR) function.
Patients with non-classic CF often have milder symptoms,
are predominantly pancreatic sufficient, usually have
a better prognosis e and may be diagnosed relatively late in
life.7e9 Consequently, they may represent a significant
proportion of long-term survivors, especially as there is now
increased awareness of atypical disease amongst both CF
and non-CF specialists.
Some hold that survival rates are being significantly
skewed by patients with non-classic disease. Experience in
our centre suggested that this was not necessarily the case
since we had observed that many patients with classic
disease were surviving into their 40s. There are few
descriptions of patients who are approaching and surpassing
this age; most are case reports10,11 but one study of 55
patients concluded that late diagnosis is a characteristic of
many long-term survivors of CF.12
In light of the paucity of information on this CF pop-
ulation, we surveyed the older patients registered with our
specialist centre, the largest survey of such patients to
date. We hypothesised that this group would predominantly
have rare (and mild) genotypes, have been diagnosed in
adulthood and be in relatively good health with few
complications.Materials and methods
Subjects
Since 1965 details of all patients referred to the Royal
Brompton Hospital (RBH) and confirmed to have CF have
been entered onto a database. The diagnosis is based on
clinical features and a positive sweat sodium (>70 mmol/L)
or chloride (>60 mmol/L) or, in cases with a borderline
sweat test result, the presence of a known disease-causing
mutation on each CFTR gene or of an abnormal nasalyear at annual review.
For this survey, we identified all patients who had, by
October 31st 2004, reached 40 years of age (the 95th age
centile4,13) without organ transplantation. From a total of
885 patients on the database 112 were thus eligible for this
survey. Six had received lung transplants after the age of
40; information for them was used only up to the date of
transplant.
Study design and methods
We collected, from clinical notes and annual review
records, the following information: age by October 31st
2004 or of death if earlier, genotype (where available), age
and clinical presentation at diagnosis. Sputum microbiol-
ogies were based on the most recent pathogen present in
sputum on a continuous basis (>75% cultures over the last
year of records). CF associated complications were recor-
ded (pancreatic status, history of pneumothorax or major
haemoptysis, CF related diabetes (CFRD), allergic bron-
chopulmonary aspergillosis (ABPA), distal intestinal
obstruction syndrome (DIOS) and CF liver disease) as were
other important medical conditions.
The weight, height, body mass index (BMI, kg/m2),
forced expiratory volume in 1 s (FEV1) and forced vital
capacity (FVC) were recorded at 5-year intervals from the
age of 35 years until death or the end of the study period.
FEV1 and FVC were recorded on a Vitalograph spirometer
and expressed as percentages of predicted normal values
for age, sex and height.14 The total number of courses of
intravenous antibiotics and hospital admissions was recor-
ded from the age of 35 years until death or the end of the
study period. Yearly averages were calculated for each five-
year period.
These data were compared with the entire UK adult CF
population4 or, where comparative figures were not avail-
able, with information from the US Cystic Fibrosis Foun-
dation (CFF) patient registry.13 The reference populations
were added to give readers better insight to the overall
profile of adult CF on a national level along with the in
depth profile we describe in our centre population. In some
categories data were not available on all cases or for every
five-year period. Differences between our group and the
reference populations were tested by Fisher’s exact test.
Informed written consent was obtained from all patients for
their anonymised data to be included in the database for
research purposes.
Results
The entire adult (16þ years) UK CF population in 2003
comprised 3989 patients; the majority (54%) was 16e25
years of age and 17% were older than 35 years.4 In the
present study we describe the characteristics of 112
patients over 40 years of age. Sixty four (57%) were male,
a proportion no different from that in the entire adult UK
CF population (56.2%, pZ 0.92). The median age at death
or at the end of the study period was 43.1 years (range
40.0e71.1) e a figure very similar to the median age of
death (42.8 years). Twenty eight percent were diagnosed in
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Figure 1 Age at diagnosis.
Table 2 The disease characteristics of the study group.
Disease
characteristics
Study
group
(%)
Reference
population -
% (35þ)
p valuea (35þ)
Organism in sputum
P. aeruginosa 76 63 (51) 0.005 (<0.001)
S. aureus 48 24 (25) <0.001 (<0.001)
H. influenzae 17 6 (4) <0.001 (<0.001)
B. cepacia 9 6 (6) 0.675 (1.0)
S. maltophilia 2 11 - US 0.008
MRSA 3 11 - US 0.024
Aspergillus
fumigatus
3 6 0.29
Complication
Pancreatic
insufficiency
82 90 - US 0.01
DIOS 36 28 0.105
CFRD 27 21 (33) 0.197 (0.238)
Significant
haemoptysis
14 9 - US <0.001
Growing old with cystic fibrosis 631their first year of life and 32% after 16 years of age (Fig. 1).
In the UK CF population, 12% of new CF diagnoses in 2003
were made after age 16, a proportion significantly lower
than in our group (p< 0.001).
The most common clinical presentations leading to
diagnosis were respiratory disease (46%), followed by
malabsorption (28%) and failure to thrive (24%). Fifteen
percent were initially investigated following diagnosis in
a relative. Less common presentations included rectal
prolapse (4%), meconium ileus (4%), DIOS (2%), recurrent
sinusitis (1%) and polyarthropathy (1%).
Genotype was available for 93 (83%) patients. Thirty
percent (nZ 34) were homozygous for the DF508 mutation,
a figure significantly lower than that for the total UK adult
CF population of 50% (p< 0.001) (Table 1). Although 12
different mutant allele combinations were present, the
majority (76%) carried at least one DF508 mutation,
a proportion a little lower than in the UK CF population
(85%, pZ 0.03). Of the known DF508 compound heterozy-
gotes (ie. DF508/other; nZ 16), the second mutation was
mild in four patients e R117H (nZ 3) and R347P. The
remaining second mutations were G551D (nZ 4), G542X
(nZ 3), N1303K (nZ 2), G85E (nZ 1), 1717 1G/ A
(nZ 1) and 621þ 1G/ T (nZ 1). Among those diagnosed
after 16 years of age, 8% (nZ 3) were homozygous for
DF508 and 67% were heterozygous (nZ 24).Table 1 The genotype of the study group compared with
the entire UK adult (16þ years) CF population.
Genotype Number of
patients
Study
group (%)
(nZ 112)
UK reference
population (%)
(nZ 3989)
p value
DF508/508 34 30 50 <0.001
DF508/N 36 32 13 <0.001
DF508/other 16 14 22 0.062
Other/N 5 4 2 0.095
N/N 1 1 3 0.378
Other/Other 1 1 4 0.095
NZ unidentified gene, otherZ any identified CF allele that is
not DF508.Sputum cultures were varied with a large number of
different pathogens; often more than one pathogen was
present (Table 2). Pseudomonas aeruginosa was the mostCF Liver disease 14 20 0.147
Pneumothorax 11 7 - US 0.195
Nasal polyps 14 4 <0.001
ABPA 10 3 0.002
Osteoporosis 8 10 - US 0.632
CF arthropathy 3 5 0.361
a Study group was compared with the entire UK adult CF
population (16þ years and 35þ years of age where stated)
unless stated as US which was taken from the CFF registry
(adults, 18þ years) and published pneumothorax29 and hae-
moptysis data.30 Definition of complications: pancreatic insuf-
ficiency - taking pancreatic enzymes, CFRD e taking
hypoglycaemic agent (insulin or oral agent), DIOS and ABPA e
clinical diagnoses, CF liver disease e abnormal liver enzymes
with no other precipitating cause, significant haemoptysis -
>100 mls blood in one episode and pneumothorax e all types.
Table 3 Period prevalence of other medical conditions present in the study population.
n (%) 8 (7) 6 (5) 4 (4) 3 (3) 2 (2) 1 (1)
Medical condition
(ever)
Depression GORD Malignancy
a
Epilepsy
Cataracts Retinopathy
CVA
Renal stones
Hypertension
IHD
Renal impairment
Hyperparathyroidism
Rheumatoid arthritis
Crohns disease
OSA
a Malignancies were pancreatic, breast, colonic and chronic lymphocytic leukaemia. GORDZ gastro-oesophageal reflux, CVAZ cer-
ebrovascular accident, IHDZ ischaemic heart disease and OSAZ obstructive sleep apnoea.
632 N.J. Simmonds et al.common pathogen (isolated in 75% of men and 83% of
women), followed by Staphylococcus aureus and Haemo-
philus influenzae. Three percent (nZ 3) cultured non-
tuberculous mycobacteria.
The most common complication after respiratory infec-
tion was pancreatic insufficiency, followed by DIOS and
CFRD (Table 2). Of the patients diagnosed after 16 years of
age, 56% were pancreatic insufficient. The median age of
diagnosis of diabetes was 35 years (range 10e57). Other
medical conditions were not common (Table 3).
There was wide variation in the patients’ BMI (Fig. 2)
although median values were generally within normal limits
(20e25 kg/m2). FEV1 was affected more severely than FVC
but both were also relatively constant across the period of
measurement (Fig. 3). The BMI and FEV1 for the entire adult
UK CF population in 2003 were very variable but themajority
(nZ 1562; 64%) had a BMI between 19 and 25 kg/m2 and
1247 (52%) had an FEV1 between 50 and 89% predicted.
4
Hospital admissions and courses of intravenous antibi-
otics closely correlated with each other; the average
annual rate of admission to hospital and of intravenous
antibiotic courses was less than one per year (Fig. 4). At 40
years of age, those patients who were homozygous for
DF508 had a median BMI of 20.9 kg/m2 (range 17.4e28.7)
and a median FEV1 of 53.2% predicted (range 16e100%). In
the five years leading up to their 40th birthday they
required on average 0.7 (range 0e2.6) courses of intrave-
nous antibiotics and 0.4 (range 0e1.6) admissions per year.
Fifty eight percent (nZ 65) of the patients were
married, 39% (nZ 44) were in full time employment and
11% (nZ 12) were working part time. 23 (21%) patients (170
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Figure 2 Median BMI values (women) had biological children. A further nine (8%)
patients had adopted or fostered a child.
Of the 112 patients surveyed 28 (25%) had died. Causes
of death included respiratory failure (nZ 16), massive
haemoptysis (nZ 2), metastatic pancreatic carcinoma
(nZ 1), gastrointestinal bleeding (nZ 1) and suicide
(nZ 1).Discussion
We describe here the largest survey of older patients with
CF, assessing some of their clinical characteristics and the
burden of their illness. A high proportion had features
suggestive of classic disease with 82% of them pancreatic
insufficient, 30% homozygous for DF508 and 68% diagnosed
before their 16th birthday. Lung function and BMI were
relatively well preserved across the group and the average
number of hospital admissions and intravenous antibiotics
courses was low, suggesting that disease burden was
perhaps not as high as initially thought.
These findings raise a number of important issues,
including the recognition of significant disease heteroge-
neity in long-term survivors. This is important as many of
the factors present in this study population are thought to
be indicators of poor prognosis; it must be presumed that
other, more important factors have influenced long-term
outcome. It is also noteworthy that the patients repre-
sented in this study had to be born before November 1964
to fulfil our age criterion; of those diagnosed as babies or
children, the reported prognosis would have been grave50 55 60 65+
 (years)
n=22 n=11 n=3 n=3
range) at 35 years onwards.
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Figure 3 Median lung function (range) at 35 years onwards.
Growing old with cystic fibrosis 633(median survival <20 years before 1970s15). The proportion
of patients who were homozygous DF508 was 30% which is
lower than in the entire adult CF population but a demon-
stration that even patients with the most common ‘severe’
mutation can achieve long-term survival.16 Additionally, of
the DF508 compound heterozygote patients, only 25% of
those had a ‘mild’ second mutation. This serves to highlight
the complexity of CF with its lack of genotypeephenotype
correlation and considerable variability in outcome.
P. aeruginosa in sputum is reported to be associated
with a worse prognosis17 but was not uncommon in this
group. This apparent paradox may have been due to pro-
portionally less mucoid strain18 and other factors associ-
ated with a worse outcome such as earlier acquisition.19
Female sex is also considered a worse prognostic factor in
the context of P. aeruginosa infection20 but we found that
rates of this infection were higher in women. High rates of
S. aureus and H. influenzae were found in our study group
relative to the general adult CF population. These organ-
isms are usually acquired in childhood and H. influenzae
often disappears after this period. The impact of these0
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onwards.bacteria on disease progression in the older patient group
is therefore not clear, although their pathogenicity is
debatable in CF.21 We found, in comparison to the general
adult CF population, low rates of MRSA and Steno-
trophomonas maltophilia, which may relate to local
infection control measures and/or lower antibiotic
availability in their former years, although the clinical
significance of MRSA and S. maltophilia in CF is not
clear.22e24 The prevalence of non-tuberculous mycobac-
teria was very low in the study group. This contrasts with
a previous study which reported a high rate of isolation of
non-tuberculous mycobacteria in patients aged over 40
years.12 The reason for this difference is not clear,
although, in part, may be explained by ascertainment bias.
The prevalence of CFRD is known to increase with age25
and has been reported to be as high as 32% in patients aged
>25 years.26,27 It is usually associated with a worse prog-
nosis, especially in female patients.28,29 27% of our pop-
ulation had CFRD. This was not significantly higher than in
the entire UK adult CF population (21%) which, in part, may
be explained by the lower rate of pancreatic insufficiency0-5
4
55
-59
60
-64 65
+
 (years)
=17
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and hospital admissions for each 5-year period from 35 years
634 N.J. Simmonds et al.in our population. The high prevalence of ABPA was unex-
pected as it is usually associated with worse lung function.
It is possible that these patients were reviewed more
frequently and more closely monitored which may have
conferred a more positive outcome; alternatively a diag-
nostic time bias may have existed as they had a longer
period of time available for the diagnosis to be made. Other
CF related complications were found at similar rates to the
entire adult CF population, including DIOS, CF liver disease,
pneumothorax, osteoporosis and CF arthropathy, although
numbers in some groups were small. Directly comparing
these factors is fraught with difficulty due to differences in
definitions between databases. For example, based on the
UK database, the prevalence of pneumothoraces is only 1%
as it includes only those instances requiring a chest drain.
However, a recent review of all types of pneumothoraces30
based on 28,191 patients in the US CFF database confirmed
a prevalence of 7.2% in the adult population (18þ years).
Based on this value there was not a difference between the
two groups.
One of the striking features of this study is that physical
parameters were relatively well preserved at each 5-year
increment from age 35 years. Courses of IV antibiotics and
hospital admission also remained low over the same age
range. These figures may be an underestimate since while
we know that the majority of patients were solely treated
at a single specialist centre, some will have been admitted
to other hospitals and received antibiotic courses else-
where without our knowledge. The prevalence of other
medical conditions, including hypertension and malignancy,
shows that common age-related illnesses are beginning to
emerge in CF but at present these rates are low. As survival
increases, they are likely to become more common and
require increasing access to more medical services. This
study also shows that having CF does not preclude individ-
uals from normal social interactions as many were married,
employed and had children.
The only other study to assess a population of patients at
this age concluded that patients diagnosed as adults differ
distinctly from long-term survivors diagnosed as children,
with less DF508 homozygosity and less pancreatic insuffi-
ciency.12 Our findings lend this description some support; of
the patients diagnosed in adulthood, just 56% of our group
were pancreatic insufficient and only 8% were homozygous
DF508. However our findings indicate also that increasing
numbers of patients with features suggestive of classic
disease are now reaching 40 years with reasonable lung
function and BMI and relatively little use of hospital
resources.
We compared our group with all adults with CF on a UK
database - or where necessary an equivalent US database.
Our study group of older patients is actually contained
within the UK database but represents less than 3% of its
population. We could not make comparisons with only the
remaining 97% so the whole adult population was used,
but any consequent error will have been very small.
Additionally, we could not compare all our findings with
CF patients over 40 years of age from other centres as
very limited published data are available. Therefore, it is
not possible to say if our findings are applicable to the
adult CF population in general or are a centre-specific
phenomenon. However, where available, a comparisonwas also made with the UK CF population over 35 years of
age and the results were unchanged. Further evaluation
of older patients across Europe and North America is
required to confirm if these findings can be generalised
across the CF populations.
Cross-sectional studies of ‘surviving’ populations need to
be interpreted with unusual care. It is wrong, for example,
to assume that the characteristics of such a population
reflect or are even related to the determinants of their
longevity. Indeed the opposite is more likely to be true;
that some of these characteristics are the result of such
survival since their likelihood of occurrence can only
increase with time. We did not set out to identify specific
factors that determine longevity but to demonstrate that
long-term survival can occur e and increasingly frequently
does - even in patients traditionally thought to have a poor
prognosis. Our findings confirm the complexity of CF and
generate a number of important hypotheses. Is the variable
outcome predominantly influenced by genetic factors,
including modifier genes and variations in CFTR function, or
are clinical factors such as BMI, lung function or CFRD
equally, or more, important? Is there an optimal age to
reach when the risk of a good outcome can be predicted
with greater certainty? How have advances in CF therapies
impacted long-term survival and how important are envi-
ronmental factors? Such questions require very carefully
controlled epidemiological studies of large populations of
older patients and more precise assessments of CFTR
function.
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